MIEN1 (Migration and Invasion Enhancer 1), also known as C35 or C17orf37. is a protein encoded by the *MIEN1* gene located on chromosome 17q25.3. Initially identified as an overexpressed gene in breast cancer, MIEN1 plays a critical role in promoting tumor cell migration, invasion, and metastasis by regulating cytoskeletal dynamics and signaling pathways, including the activation of Rho GTPases. Its expression is linked to poor prognosis in multiple cancers, such as breast, prostate, and ovarian cancers.
MIEN1 antibodies are immunological tools designed to detect and quantify MIEN1 protein levels in biological samples. These antibodies are essential for studying MIEN1's functional role in cancer progression, including its involvement in EMT (epithelial-mesenchymal transition) and interaction with signaling molecules like EGFR. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence to assess MIEN1 expression patterns in tumor tissues or cell lines.
Research utilizing MIEN1 antibodies has highlighted its potential as a diagnostic biomarker or therapeutic target. Recent studies also explore its role beyond oncology, including viral infection responses. Validation of MIEN1 antibody specificity remains crucial, as cross-reactivity with unrelated proteins could affect data interpretation. Overall, MIEN1 antibodies are vital for advancing understanding of tumor metastasis mechanisms and developing targeted therapies.